5-Amino-1MQ vs SLU-PP-332
5-Amino-1MQ is a cell-permeable small-molecule inhibitor of nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide and thereby consumes S-adenosylmethionine and diverts nicotinamide away from NAD+ salvage. SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, orphan nuclear receptors that act with PGC-1 coactivators to regulate mitochondrial biogenesis and oxidative metabolism. They are paired because both are marketed with metabolic and exercise-mimetic framing and both are small molecules rather than peptides. No study has tested them against each other, and the more consequential fact is what they share: both are preclinical-only, with no published or registered human clinical trial, so neither has human pharmacokinetics, dosing, efficacy or safety data of any kind.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered 5-amino-1MQ and SLU-PP-332 together or compared them in parallel arms, in any model, in vivo or in vitro. Searches of PubMed and Europe PMC returned no record naming both compounds at all, not even a review placing them in adjacent sections, which is unusual and reflects how separate the two research communities are: one sits in NNMT enzymology and obesity pharmacology, the other in nuclear receptor pharmacology and exercise physiology. Any comparison is therefore indirect and assembled from rodent studies and cell work that used different species, different disease models, different endpoints and different readouts of metabolic effect. It is also a comparison between two bodies of evidence at the same stage of development, which means the usual asymmetry does not apply: neither compound has been given to a human in a published trial, so there is no clinical evidence on either side to weigh.
Side by side.
| 5-Amino-1MQ | SLU-PP-332 | |
|---|---|---|
| Evidence maturity | Preclinical only | Preclinical only |
| Studies cited here | 15 | 13 |
| Published 2023 or later | 8 | 13 |
| Newest paper | 2026 | 2026 |
| Molecular class and target | A small-molecule quinolinium enzyme inhibitor, 5-amino-1-methylquinolinium, acting on nicotinamide N-methyltransferase. The mechanism is inhibition of an enzyme that consumes substrate. | A synthetic small-molecule agonist of a nuclear receptor family, activating ERRalpha, ERRbeta and ERRgamma. The mechanism is transcriptional, working through PGC-1 coactivation. |
| Proposed downstream effect | Increased NAD+ salvage flux and altered methylation potential, with reported changes in adipose polyamine flux, adipose NAD+ levels, lipogenic gene expression and AMPK activation in skeletal muscle. 1-methylnicotinamide serves as the biomarker of target engagement. | Reproduction of part of the acute aerobic exercise transcriptional programme in skeletal muscle, with increased mitochondrial biogenesis, fatty acid oxidation, type IIa oxidative fibre content and TFEB-linked autophagy gene transcription. |
| Best-studied models | Diet-induced obese mice and ob/ob mice for body weight and glucose tolerance, aged mouse skeletal muscle and muscle stem cells for regeneration and grip strength, a sarcopenia model, and a mouse hindlimb ischaemia model of peripheral artery disease. | Mice for treadmill endurance and skeletal muscle transcriptomics, diet-induced obese and ob/ob mice for energy expenditure and fat mass, a pressure-overload transverse aortic constriction heart failure model, and 21-month-old mice for renal ageing. |
| Independent pharmacological confirmation | Present at the target level. Separate groups have reported metabolic benefit with structurally distinct NNMT inhibitors, including the JBSNF series and a tricyclic chemotype, providing independent confirmation of NNMT as a metabolic target rather than of this specific molecule. | Largely concentrated around the originating chemistry programme and its analogues, including SLU-PP-915, with a 2025 ex vivo pilot in primary myoblasts from physically inactive women representing one of the few contributions from an outside group. |
| Evidence maturity | Preclinical only. No human clinical trial has been published, and human pharmacokinetics, oral bioavailability, safety and dosing are uncharacterised in the peer-reviewed literature. | Preclinical only. A ClinicalTrials.gov query returned no studies, so human pharmacokinetics, dosing, efficacy and safety are entirely unestablished, and long-term toxicity, carcinogenicity and reproductive effects have not been characterised. |
| What has actually been measured in humans | Nothing from administration. No biomarker-controlled human study has confirmed target engagement, so even the 1-methylnicotinamide readout that works in rodents has not been demonstrated to respond in people. | Nothing from administration either. The one study with human-derived material treated primary myoblasts isolated from physically inactive women ex vivo; no participant received the compound. |
| Unresolved mechanistic risks | Long-term consequences of sustained NNMT inhibition on methylation potential, polyamine metabolism and tumour biology are unresolved. Enzyme kinetics work has also shown that some inhibitors are themselves substrates undergoing turnover into more potent methylated metabolites, complicating exposure. | Chronic activation of a receptor family governing mitochondrial biogenesis has no characterised long-term profile. Structure-activity work is still resolving which analogues favour ERRalpha over ERRgamma, and the heart failure work identified ERRgamma as the principal mediator in that model. |
And what it does not.
This is a comparison between two compounds at the same stage of evidence, and that stage is early. Neither has a published or registered human clinical trial, so for both of them human pharmacokinetics, oral bioavailability, dosing, efficacy and safety are unestablished, and no biomarker-controlled study has confirmed target engagement in a person. What each supports separately is a coherent rodent story. For 5-amino-1MQ, NNMT inhibition reduced body weight and improved glucose tolerance in diet-induced obese mice, improved grip strength and regeneration in aged muscle, and produced additive effects alongside calorie restriction or exercise training; the target has independent pharmacological confirmation from structurally distinct inhibitors, which is a genuine strength, though that confirms the target rather than this molecule. For SLU-PP-332, pan-ERR agonism reproduced an acute aerobic exercise transcriptional signature and improved treadmill endurance in mice, reduced fat mass in obese mice, and improved ejection fraction and survival in a pressure-overload heart failure model; its evidence is more concentrated around the originating chemistry programme. Neither literature establishes that these rodent findings transfer to humans, and open mechanistic questions differ in kind rather than in seriousness: sustained methylation and polyamine effects on one side, uncharacterised chronic nuclear receptor activation on the other.
Common questions.
- Has either of these two compounds been given to a human in a published study?
No. Neither has a published or registered human clinical trial. For SLU-PP-332 a ClinicalTrials.gov query returned no studies at all. For 5-amino-1MQ no human trial appears in the peer-reviewed literature, and no biomarker-controlled human study has confirmed target engagement. All reported metabolic, muscular, cardiac and renal outcomes for both compounds come from rodents or cell culture.
- Do the two act on the same metabolic pathway?
They do not, though both touch cellular energy metabolism. 5-Amino-1MQ inhibits nicotinamide N-methyltransferase, an enzyme whose activity consumes S-adenosylmethionine and diverts nicotinamide away from NAD+ salvage. SLU-PP-332 activates the estrogen-related receptors, a nuclear receptor family that works with PGC-1 coactivators to drive transcription of mitochondrial biogenesis and fatty acid oxidation programmes.
- Which of the two has more independent laboratories behind it?
The NNMT target has broader independent pharmacological confirmation, with separate groups reporting metabolic benefit from structurally distinct inhibitors including the JBSNF series and a tricyclic chemotype. That confirms the target rather than the specific molecule. The SLU-PP-332 record is more concentrated around the originating chemistry programme and its analogues, with one ex vivo pilot in human-derived myoblasts from an outside group.
- Why do doping-control papers keep appearing for these compounds?
Because anti-doping laboratories characterise metabolites of compounds circulating in unregulated markets before any clinical evidence exists. Two 2026 studies profiled SLU-PP-332 metabolites in human liver preparations, one identifying nine and the other twenty-two, with eight proposed as screening targets. Those papers address detectability in urine and plasma and generate no efficacy or safety information.
- What are the main unresolved safety questions for each compound?
For 5-amino-1MQ the published record flags the long-term consequences of sustained NNMT inhibition on methylation potential, polyamine metabolism and tumour biology, and enzyme kinetics work has shown that some inhibitors are themselves substrates that turn over into more potent methylated metabolites. For SLU-PP-332 long-term toxicity, carcinogenicity and reproductive effects have not been characterised at all.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.